Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Varicella vaccine.

S A Chartrand1

  • 1Department of Pediatrics, Creighton University, Omaha, Nebraska, USA.

Pediatric Clinics of North America
|April 13, 2000
PubMed
Summary
This summary is machine-generated.

The varicella vaccine is safe and effective for all ages, offering milder illness from breakthrough infections and reduced herpes zoster risk. Improved vaccines with better storage are forthcoming.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization and mechanisms of resistance of group B streptococcal isolates obtained at a community hospital.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2005
Same author

Severe intrauterine herpes simplex disease with placentitis in a newborn of a mother with recurrent genital infection at delivery.

Journal of perinatology : official journal of the California Perinatal Association·2002
Same author

The heptavalent conjugate pneumococcal vaccine and its implications for managed care--clinical overview and roundtable discussions.

Managed care interface·2001
Same author

Activity of faropenem against resistant isolates of Streptococcus pneumoniae.

Diagnostic microbiology and infectious disease·2001
Same author

Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.

Diagnostic microbiology and infectious disease·2001
Same author

Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.

The Journal of antimicrobial chemotherapy·1999
Same journal

Barriers, Breakthroughs, and the Future of Pediatric Dermatologic Care.

Pediatric clinics of North America·2026
Same journal

Advancing Pediatric Dermatology: Innovations in Care and Access.

Pediatric clinics of North America·2026
Same journal

No Child Left Behind: Advancing Access in Pediatric Dermatology, a 4-Year, Single-Center Experience.

Pediatric clinics of North America·2026
Same journal

Telemedicine and Access to Pediatric Dermatology Care.

Pediatric clinics of North America·2026
Same journal

Inequitable Reimbursement for Pediatric Providers: A Review of Structural Factors that Disincentivize the Care of Children.

Pediatric clinics of North America·2026
Same journal

Medical Photography's Power to Change Medical Care.

Pediatric clinics of North America·2026
See all related articles

Area of Science:

  • Immunology
  • Vaccinology
  • Public Health

Background:

  • Varicella (chickenpox) remains a concern, particularly for potential complications.
  • The current varicella vaccine has demonstrated significant public health benefits.
  • Understanding vaccine effectiveness and safety is crucial for ongoing disease prevention.

Purpose of the Study:

  • To evaluate the safety, efficacy, and cost-effectiveness of the varicella vaccine.
  • To assess the impact of vaccination on breakthrough varicella and herpes zoster incidence.
  • To review evidence regarding vaccine immunity duration and future vaccine developments.

Main Methods:

  • Systematic review of existing literature on varicella vaccination.
  • Analysis of clinical trial data and post-marketing surveillance reports.

Related Experiment Videos

  • Comparative assessment of vaccinees versus unvaccinated individuals regarding varicella and herpes zoster outcomes.

    • Main Results:

    • Varicella vaccine is safe, effective, and cost-effective in children, adolescents, and adults.
    • Breakthrough varicella cases post-vaccination are milder than wild-type infections.
    • No severe adverse events linked to the vaccine; reduced herpes zoster incidence observed.

    Conclusions:

    • The varicella vaccine provides robust protection with a favorable safety profile.
    • Current evidence does not indicate waning immunity, supporting long-term protection.
    • Advancements in varicella vaccine technology promise enhanced efficacy and logistical benefits.